HomeGeneticsConditionsMyotonic dystrophy
Back to Conditions
Myotonic dystrophy
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Conditions

Myotonic dystrophy

Myotonic dystrophy is a common form of adult-onset muscular dystrophy characterized by progressive muscle weakness and the inability to relax muscles after contraction.

Overview

Myotonic dystrophy is an inherited disorder involving progressive muscle wasting and weakness. A hallmark symptom is myotonia—prolonged muscle contractions that make it difficult to release a grip or relax muscles after use. Other common features include cataracts, cardiac conduction defects, and diabetes mellitus.

Types

  • Type 1: Often affects distal muscles (lower legs, hands, neck, and face). It includes a congenital form that can be life-threatening at birth.
  • Type 2: Tends to be milder than type 1 and primarily affects proximal muscles (neck, shoulders, elbows, and hips).

Causes

Both types are caused by DNA segments that are abnormally repeated many times, creating an unstable region in the gene:

  • Type 1: Caused by mutations in the DMPK gene.
  • Type 2: Caused by mutations in the CNBP gene.

These mutations result in an unusually long messenger RNA (molecular blueprint) that forms clumps inside the cell. These clumps interfere with the production of other essential proteins, preventing muscle and other tissues from functioning normally.

Inheritance

Myotonic dystrophy is inherited in an autosomal dominant pattern, meaning one copy of the altered gene is sufficient to cause the disorder. In type 1, the disorder exhibits anticipation, a phenomenon where the unstable region of the gene increases in length as it is passed to subsequent generations, causing the condition to appear earlier and with greater severity.

Frequently Asked Questions

Baseline ECG and echocardiogram are recommended at diagnosis, followed by annual ECGs; if abnormalities appear, a Holter monitor or event recorder should be performed every 1–2 years, and more often if symptoms (palpitations, syncope) develop.
void triggering agents such as succinylcholine and volatile anesthetics that can exacerbate myotonia; use short‑acting non‑depolarizing muscle relaxants, provide adequate warming, and have a rapid‑acting antimyotonic drug (e.g., intravenous magnesium or a low dose of a benzodiazepine) ready.
Low‑impact, supervised aerobic activities (e.g., swimming, stationary cycling) and gentle resistance training can maintain strength and flexibility without provoking myotonia; avoid sudden, forceful contractions and cold environments, which can trigger stiffness.
Both partners can undergo targeted testing for the known DMPK (type 1) or CNBP (type 2) mutation; if one is a carrier, options include prenatal diagnosis via chorionic villus sampling or amniocentesis, and pre‑implantation genetic testing with IVF to select embryos without the expanded repeat.===
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ